6667 Stock Overview
Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China.
Mega Genomics Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$16.26|
|52 Week High||HK$21.00|
|52 Week Low||HK$10.10|
|1 Month Change||41.39%|
|3 Month Change||-6.34%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-9.67%|
Recent News & Updates
|6667||HK Healthcare||HK Market|
Return vs Industry: Insufficient data to determine how 6667 performed against the Hong Kong Healthcare industry.
Return vs Market: Insufficient data to determine how 6667 performed against the Hong Kong Market.
|6667 Average Weekly Movement||11.7%|
|Healthcare Industry Average Movement||8.3%|
|Market Average Movement||8.1%|
|10% most volatile stocks in HK Market||14.9%|
|10% least volatile stocks in HK Market||4.1%|
Stable Share Price: 6667 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: Insufficient data to determine 6667's volatility change over the past year.
About the Company
Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services comprising ApoE gene testing package that assesses the lipid metabolism capacity and the risk for various related diseases, including Alzheimer’s disease; folate metabolic capacity assessment, which analyzes genes related to folate metabolism capacity to determine the risk of developing hyperhomocysteinemia, cardiovascular, and cerebrovascular diseases; Parkinson’s disease risk assessment; full-scale cancer risk assessment package; and cardiovascular and cerebrovascular disease risk assessment package. The company also provides advanced testing services, which include Hereditary breast cancer/ovarian cancer genetic testing, Septin9 colorectal cancer screening test, and RNF180/Septin9 gastric cancer screening test; and executive testing services, such as personal whole genome test and whole-exome sequencing package for adults.
Mega Genomics Limited Fundamentals Summary
|6667 fundamental statistics|
Is 6667 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6667 income statement (TTM)|
|Cost of Revenue||CN¥71.29m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.26|
|Net Profit Margin||25.84%|
How did 6667 perform over the long term?See historical performance and comparison